Triptorelin: A Tracking Guide for a GnRH Agonist

Triptorelin is a synthetic GnRH (gonadotropin-releasing hormone) agonist. Sustained-release depot forms are used clinically for prostate cancer, endometriosis, and central precocious puberty — contexts where the goal is sustained suppression of the HPTA axis via receptor downregulation. Self-experimenter use as a short-acting single-dose "post-cycle restart" for the HPTA is off-label and rests on a thin evidence base.

What it does

GnRH agonists initially stimulate pituitary release of LH and FSH (the "flare" effect). With sustained exposure, receptors downregulate and gonadotropin output is suppressed — the clinical use case. A single bolus of immediate-release triptorelin produces a pronounced flare, which is the basis for the off-label HPTA-restart use.

Typical protocol shape

• Clinical (prostate cancer, endometriosis): sustained-release depot, monthly or quarterly, intended for chronic suppression
• Off-label self-experimenter restart: single immediate-release subcutaneous dose, often after a suppressive androgen cycle

These are completely different use cases. Do not confuse them.

What to track daily

For a single-dose restart attempt:

• Day of administration, dose, route, site
• Daily morning energy (1 to 10)
• Libido (1 to 10)
• Sleep quality
• Mood
• Any side effects (injection-site reaction, headache, transient flush)

What to track weekly

• Body weight
• Training performance at benchmark lifts
• Morning erections (presence or absence)
• Resting heart rate

Bloodwork worth doing

This is the entire point of running triptorelin in a restart context — if you are not doing labs, you cannot evaluate anything:

• Pre-cycle: total testosterone, free testosterone, LH, FSH, estradiol, SHBG, prolactin
• 2 weeks post: LH, FSH, total T
• 4 weeks post: full panel repeat
• 8 weeks post: full panel repeat

The question you are answering: did LH and FSH come back, and did endogenous testosterone follow.

Realistic expectations

Even in the best self-experimenter reports, recovery from a suppressive androgen cycle is measured in months, not weeks. A single triptorelin dose is one input; sleep, body fat, prior cycle length and compounds, age, and baseline HPTA function all matter more. Anyone selling you a "one shot restart" narrative is overselling.

If you are in chronic suppression from clinical depot use, the timeline to recovery is very different and is a physician-level conversation.

Common mistakes

• Running triptorelin without pre- and post-cycle bloodwork. You learn nothing.
• Treating it as a substitute for SERMs or HCG. It plays a different role mechanistically.
• Repeated dosing in short succession. Each repeat dose risks downregulation rather than restart.
• No data on the suppressive cycle that preceded it. Restart only makes sense in the context of what put you down.

A tracking template

• Week minus 2: baseline labs and daily metrics
• Day 0: triptorelin dose
• Weeks 1 to 8: daily metrics, weekly labs as listed
• Decision point at week 8: is HPTA recovering on its own, or do you need a physician-managed plan

Safety notes

Triptorelin affects a major endocrine axis. The flare effect can cause a transient symptom worsening in some clinical contexts. Off-label self-experimenter use is not benign. Discuss with a physician, ideally one familiar with HPTA recovery, before considering this. Do not run blind.

Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.